
This study investigated the effects of early administration of the antiresorptive drug denosumab on bone metabolism in previously healthy patients. The primary endpoint was group differences in the percentage change of C‐terminal telopeptide of type 1 collagen (CTX‐1) levels in serum from denosumab/placebo application to four weeks thereafter. Changes in serum levels of bone formation markers and urinary calcium excretion were secondary outcome parameters. The investigation proved that a single application of denosumab early after admission to an ICU prevents a sharp immobilization‐associated increase in bone resorption among previously healthy individuals.
Like
Save
Share